Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Fresenius Medical (FMS) Q1 Earnings & Sales Lag Estimates

Fresenius Medical Care AG & Co. KGAA FMS reported adjusted earnings of 37 cents per American Depositary Share (ADS) in the first quarter of 2016, missing the Zacks Consensus Estimate by a nickel. However, earnings per ADS increased 8.2% from the year-ago quarter.

Revenues increased 6.2% (9% at constant currency) on a year-over-year basis to $4.21 billion but missed the Zacks Consensus Estimate of $4.22 billion.

Segment Details

Net Healthcare revenues grew 7.3% to $3.41 billion, with significant contribution from the North American market. Dialysis product revenues increased 1.7% to $791 million. On a constant currency basis, revenues generated from dialysis products increased 6%.

By geography, North America revenues rose 10% year over year to $3.04 billion. Revenues from the care Coordination business grew an impressive 20% to $522 million, while organic revenue growth was 17%. Dialysis business grew by 8% in the reported quarter.

EMEA revenues increased 5% to $631 million at constant currency. Product revenues increased more than 5% at constant currency to $330 million on increased sales of bloodlines, products for acute care treatments and hemodialysis solutions and concentrates.

Revenues from Asia-Pacific grew 10% at constant currency to $374 million. Net Health Care revenues were $168 million, driven by 6% growth in dialysis treatments. The product business surged more than 16% at constant currency to $206 million, driven by strong sales performance in dialysers, bloodlines, machines and peritoneal dialysis products.

Latin America revenues increased 5% at constant currency to $153 million. Dialysis treatments decreased by 6% and product revenues decreased by 4% at constant currency to $40 million.
 

Guidance

For 2016, Fresenius Medical estimates revenue growth of 7%–10% at constant currency excluding acquisitions. Net income attributable to shareholders of the company is liekly to increase around 15%–20% in 2016.

Zacks Rank & Key Picks

Currently, Fresenius Medical carries a Zacks Rank #3 (Hold).

Better-ranked stocks in the broader medical sector are Edwards Lifesciences EW, IRadimed IRMD and Masimo Corp MASI. All the three stocks sport a Zacks Rank #1 (Strong Buy).
 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. http://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&... blog">Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
FRESENIUS MED (FMS): Free Stock Analysis Report
 
MASIMO CORP (MASI): Free Stock Analysis Report
 
IRADIMED CORP (IRMD): Free Stock Analysis Report
 
EDWARDS LIFESCI (EW): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research